Ascendiant Capital Markets Lowers Alzamend Neuro (NASDAQ:ALZN) Price Target to $20.00

Alzamend Neuro (NASDAQ:ALZNGet Free Report) had its price objective cut by equities researchers at Ascendiant Capital Markets from $32.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Alzamend Neuro Stock Down 1.8 %

Shares of ALZN stock opened at $0.68 on Monday. Alzamend Neuro has a 52 week low of $0.64 and a 52 week high of $15.06. The company has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.36.

Alzamend Neuro (NASDAQ:ALZNGet Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.10. Equities research analysts predict that Alzamend Neuro will post -1.68 earnings per share for the current year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Geode Capital Management LLC acquired a new position in Alzamend Neuro, Inc. (NASDAQ:ALZNFree Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.62% of Alzamend Neuro as of its most recent SEC filing. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

Alzamend Neuro Company Profile

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

See Also

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.